HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Combined modality therapy for mediastinal Hodgkin's disease. Prognostic significance of constitutional symptoms and size of disease.

Abstract
Combined modality therapy was used in an attempt to increase the complete remission rate and survival of previously untreated patients with Hodgkin's disease. MOPP (nitrogen mustard, vincristine, procabazine, prednisone) chemotherapy was followed by radiotherapy. The median duration of follow-up exceeded 5 years. Complete remissions were achieved in 63 of 71 patients (89%) with mediastinal masses. The actuarial survival of 10 years was 72% for patients with small mediastinal masses (mediastinal mass ratio less than 0.35) and 46% for patients with large mediastinal masses (P less than 0.05). The corresponding disease-free survival figures were 69% and 46%, respectively (P less than 0.05). A small mediastinal mass did not affect prognosis. Systemic symptoms especially affected the prognosis in patients with a large mediastinal mass, since in symptomatic patients the actuarial survival and freedom from relapse were 19%, whereas all asymptomatic patients survived without relapse. In patients with a small mediastinal mass, systemic symptoms had no significant effect on the actuarial survival or disease free survival. Age and stage did not affect the prognosis in patients with large mediastinal masses. It was concluded that MOPP chemotherapy followed by radiotherapy was an adequate treatment for asymptomatic patients with large mediastinal disease. However, in symptomatic patients with large mediastinal masses, this treatment was clearly inadequate.
AuthorsA Ferrant, V Hamoir, J Binon, J L Michaux, G Sokal
JournalCancer (Cancer) Vol. 55 Issue 2 Pg. 317-22 (Jan 15 1985) ISSN: 0008-543X [Print] United States
PMID2578082 (Publication Type: Journal Article)
Chemical References
  • Bleomycin
  • Procarbazine
  • Mechlorethamine
  • Vincristine
  • Vinblastine
  • Dacarbazine
  • Doxorubicin
  • Carmustine
  • Prednisone
Topics
  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Bleomycin (therapeutic use)
  • Carmustine (therapeutic use)
  • Combined Modality Therapy
  • Dacarbazine (therapeutic use)
  • Doxorubicin (therapeutic use)
  • Drug Resistance
  • Female
  • Hodgkin Disease (drug therapy, radiotherapy, therapy)
  • Humans
  • Male
  • Mechlorethamine (therapeutic use)
  • Mediastinal Neoplasms (drug therapy, radiotherapy, therapy)
  • Middle Aged
  • Prednisone (therapeutic use)
  • Procarbazine (therapeutic use)
  • Prognosis
  • Vinblastine (therapeutic use)
  • Vincristine (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: